Abstract
Objective: A fast, specific, and sensitive high-performance liquid chromatographic method has been developed and validated for the quantitative determination of unchanged Ramipril (RAM) and Telmisartan (TEL) in animal plasma.Methods: Analytes were extracted from animal plasma, 250 µl of animal plasma sample were mixed with internal working standard (25 ngmL-1) with the further addition of chloroform (HPLC Grade, Merck). The clear organic layer was separated and reconstituted to 1 ml in mobile phase and analysed by HPLC. The method was validated and evaluated in terms of linearity, accuracy, precision, specificity, limit of detection and limit of quantitation.Results: Absorption maxima of TEL and RAM was found to be 270 and 273 nm respectively. TEL and RAM with their respective internal standards (I. S.) were found to be well separated from the co-eluted components and there were no interferences from the endogenous material. The limit of detection (LOD) and limit of quantitation (LOQ) were found to be 2.01±.05; 4.88±0.10 and 0.11 and 0.25 for TEL and RAM respectively on the basis of a signal to noise ratio. The ruggedness of the method at various parameters was found to be±1.94% and±1.02% for TEL and RAM respectively. The low values of %RSD (<2.0) for each of the drug proposed that during all deliberate variations, middle-quality control (MQC) was not affected and it was in accordance with that of actual.Conclusion: Thus developed High-Performance Liquid Chromatography (HPLC) method was found to be more accurate, precise, sensitive, selective and reproducible.
Highlights
Telmisartan (TEL) and Ramipril (RAM) are a safe and effective alternative for the treatment of hypertension
TEL chemically 4’-[(1, 4’-Dimethyl-2’-propyl-[2, 6’-bi-1Hbenzimidazol]-1’-yl) methyl]-[1, 1’-biphenyl]-2-carboxylic acid, is a nonpeptide angiotensin-II receptor antagonist, which selectively and insurmountably inhibits angiotensin-II AT1 receptor subtype without affecting other systems involved in cardiovascular regulation [1]
RAM is official in United States of pharmacopoeia (USP) and British
Summary
Telmisartan (TEL) and Ramipril (RAM) are a safe and effective alternative for the treatment of hypertension. RAM is a prodrug and nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity [1]. RAM is converted in the liver by deesterification into its active form ramiprilat, which inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. TEL work by blocking the effect of a chemical called angiotensin II found in bloodstream. Angiotensin II causes blood vessels to narrow, so by blocking this effect. TEL allows blood vessels to relax and widen. As this happens, the pressure within blood vessels is reduced. RAM is official in United States of pharmacopoeia (USP) and British
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
